急性心肌梗死患者链激酶加速溶栓疗法的多中心临床试验

目的 观察链激酶（ＳＫ）加速溶栓疗法治疗急性心肌梗死（ＡＭＩ）能否提高疗效的可能性恶性循环 。方法 由全国５０家系统组成协作组自１９９６年４月１日至１９９７年７月６日采用ＳＫ加速溶栓疗法（１５０万Ｕ，３０ｍｉｎ，内静脉滴入）治疗ＡＭ患共５２８例，观察临床疗效、不良反应及病死率。结果 ５周总病死率为６．６％（３５／５２８），闭塞相关血管临床再灌注率为７９．７８％（４１２／５２８），出血发生率为２．

A report on multicenter clinical trial of thrombolytic therapy using accelerated streptokinase dose regimen in patients with acute myocardial infarction

Objective To observe the clinical efficacy and safety of intravenous thrombolytic therapy using accelerated streptokinase (SK) dose regimen in acute myocardial infarction (AMI). Methods National multicenter, open, prospective, case collection study. The data were collected from 40 hospitals during April 1996 to July 1997. The clinical therapeutic efficacy, adverse events and mortality were analyzed in 528 patients with AMI treated with accelerated SK regimen (1.5 million units within 30 min). Results The total mortality in the first 5 weeks was 6.6% (35/528). The reperfusion rate of infarct related arteries (IRAs) was 79.7% (421/528) by clinical standards. The incidence of allergic reaction and hypotension was 3.8% (20/528) and 4.2% (22/528), respectively. The incidence of bleeding was 2.7% (14/528), including cerebral bleeding 0.8% (4/528), major bleeding 0.8% (4/528). Conclusion Intravenous accelerated SK therapy can improve reperfusion rate markedly and reduce mortality without increasing adverse events such as bleeding, allergic reaction and hypotension.